A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

Also called NCT01028963

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 159 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01028963
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Czechia, Germany, Hungary, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01028963. Randomized; triple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Placebo
Intervention (Drug)
pioglitazone
Intervention (Drug)
CCX140-B
Intervention (Drug)
CCX140-B
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01028963
Content hash
a60a479cec42888808c386a7b44bf4c01e7cb67bc3e6e3d0522343b576a44a36